• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Johnson & Johnson Q2 results beat The Street, medical device sales down a third

Johnson & Johnson Q2 results beat The Street, medical device sales down a third

July 16, 2020 By Chris Newmarker

Johnson & JohnsonJohnson & Johnson (NYSE:JNJ) posted second-quarter results today that beat the consensus forecast on Wall Street — boosting its outlook for the year even as its medical device sales took a big hit from the COVID-19 pandemic.

The New Brunswick, N.J.–based medical device and pharmaceutical giant reported profits of $3.6 billion, or $1.36 per share, on sales of $18.3 billion for the three months ended June 30, 2020, for a bottom-line decline of –34.6% and a sales decline of –10.8% compared with Q4 2017.

Adjusted to exclude one-time items, earnings per share were $1.67, 19¢ ahead of The Street, where analysts were looking EPS of $1.48 on sales of $17.5 billion.

Most of J&J’s Q2 sales hit came from its medical device business, which saw a year-over-year sales decline of –33.9% as the COVID-19 pandemic caused a deferral in medical procedures. Consumer health was down –7.0%, while pharmaceuticals were up 2.1%.

Johnson & Johnson CEO Alex Gorsky in a news release touted the work the company is doing to develop a COVID-19 vaccine: “We know the need is urgent, and every day we commit to doing our part to find a solution for the global good.”

During today’s earnings call, executives added that they hope to start a late-stage human trial for a potential coronavirus vaccine ahead of schedule — in late September.

J&J expects to log adjusted EPS of $7.75–$7.95 this year, up from its prior guidance of $7.50–$7.90, and boosted its top-line outlook to $81.0–$82.5 billion, compared with $79.2–$82.2 previously.

“We often get asked about a second wave of COVID. Our thinking continues to be that, if that occurs, it should not have the same level of global impact that’s been experienced in the last 4 months. This assumption is based on opinions shared by various experts as they believe, as do we, that if this occurs, the world is much better prepared,” J&J CFO Joseph Wolk said during today’s earnings call.

JNJ shares were down slightly in late morning trading. So was MassDevice’s MedTech 100 Index,  which includes stocks of the world’s largest medical device companies, and the Dow Jones Industrial Average and S&P 500.

 

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Johnson & Johnson

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy